Anti-MET targeted therapy has come of age: The first durable complete response with MetMAb in metastatic gastric cancer

Cancer Discovery

Volumn 1, Issue 7, 2011, Pages 550-554

  Feng, Yan ^a   Ma, Patrick C ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABOZANTINIB; CRIZOTINIB; ERLOTINIB; FICLATUZUMAB; FORETINIB; MET MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; PLACEBO; PROTEIN TYROSINE KINASE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TIVANTINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ARTICLE; AUTOCRINE EFFECT; CANCER CHEMOTHERAPY; CARCINOGENESIS; DISEASE COURSE; DRUG WITHDRAWAL; GENE AMPLIFICATION; GENE OVEREXPRESSION; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; METASTASIS; ONCOGENE; OSTEOSARCOMA; OVERALL SURVIVAL; PARACRINE SIGNALING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY TUMOR; PROGRESSION FREE-SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; TISSUE REPAIR; TREATMENT RESPONSE; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT; XENOGRAFT;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS C-MET; STOMACH NEOPLASMS;

EID: 84865758495     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-11-0289     Document Type: Article

References (17)

1. Catenacci DV, Henderson L, S-Y, Xiao Penuel E, Patel P, Tauch RL. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discovery 2011;1:573-9.
2. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010;11:834-48.
3. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
4. Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 2008; 47:1025-37.
5. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-203.
6. Graveel CR, DeGroot JD, Sigler RE, Vande Woude GF. Germline met mutations in mice reveal mutation-and background-associated differences in tumor profiles. PLoS One 2010;5:e13586.
7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
8. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006;12:p. 6144-52.
9. Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008;68:4360-8.
10. Spigel DR, Ervin TJ, Ramlau R, Daniel DB, Goldschmidt JH, Blumenschein GR, et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 2011;29(suppl):abstr 7505.
11. Pacchiana G, Chiriaco C, Stella MC, Petronzelli F, De Santis R, Galluzzo M, et al. Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. J Biol Chem 2010;285:36149-57.
12. Gao CF, Xie Q, Zhang YW, Su Y, Zhao P, Cao B, et al. Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma. Mol Cancer Ther 2009;8: 2803-10.
13. Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67:4408-17.
14. Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, et al. Activity of crizotinib (PF02341066), a dual mesenchymalepithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011;6:942-6.
15. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, et al. Identification of a small and lethal subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib by MET amplification. J Clin Oncol 2011;29: suppl;abstr 4130.
16. Chi AS, Kwak EL, Clark JW, Wang DL, Louis DN, Iafrate AJ, et al. Clinical improvement and rapid radiographic regression induced by a MET inhibitor in a patient with MET-amplified glioblastoma. J Clin Oncol 2011;29:suppl;abstr 2072.
17. Wu C, Tang Z, Fan W, Zhu W, Wang C, Somoza E, et al. In vivo positron emission tomography (PET) imaging of mesenchymalepithelial transition (MET) receptor. J Med Chem 2010;53:139-46.